JP2014520847A5 - - Google Patents

Info

Publication number

JP2014520847A5

JP2014520847A5 JP2014520211A JP2014520211A JP2014520847A5 JP 2014520847 A5 JP2014520847 A5 JP 2014520847A5 JP 2014520211 A JP2014520211 A JP 2014520211A JP 2014520211 A JP2014520211 A JP 2014520211A JP 2014520847 A5 JP2014520847 A5 JP 2014520847A5

Authority

JP

Japan

Prior art keywords

antibody

subject

antigen

binding portion

pharmaceutical composition

Prior art date

2012-07-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims 33
• 102000036639 antigens Human genes 0.000 claims 33
• 108091007433 antigens Proteins 0.000 claims 33
• 239000008194 pharmaceutical composition Substances 0.000 claims 19
• 239000000203 mixture Substances 0.000 claims 11
• 208000006673 asthma Diseases 0.000 claims 10
• 230000001747 exhibiting effect Effects 0.000 claims 5
• 239000003795 chemical substances by application Substances 0.000 claims 4
• 210000002966 serum Anatomy 0.000 claims 4
• 230000008030 elimination Effects 0.000 claims 3
• 238000003379 elimination reaction Methods 0.000 claims 3
• 230000007717 exclusion Effects 0.000 claims 3
• 230000001225 therapeutic effect Effects 0.000 claims 3
• 102000004127 Cytokines Human genes 0.000 claims 2
• 108090000695 Cytokines Proteins 0.000 claims 2
• 230000003444 anaesthetic effect Effects 0.000 claims 2
• -1 anesthetic Substances 0.000 claims 2
• 239000005557 antagonist Substances 0.000 claims 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
• 150000003431 steroids Chemical class 0.000 claims 2
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
• 229930182837 (R)-adrenaline Natural products 0.000 claims 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
• 108010036949 Cyclosporine Proteins 0.000 claims 1
• 102000003951 Erythropoietin Human genes 0.000 claims 1
• 108090000394 Erythropoietin Proteins 0.000 claims 1
• 102000018997 Growth Hormone Human genes 0.000 claims 1
• 108010051696 Growth Hormone Proteins 0.000 claims 1
• 108060003951 Immunoglobulin Proteins 0.000 claims 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
• 239000003263 anabolic agent Substances 0.000 claims 1
• 230000000202 analgesic effect Effects 0.000 claims 1
• 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
• 230000003092 anti-cytokine Effects 0.000 claims 1
• 230000002682 anti-psoriatic effect Effects 0.000 claims 1
• 239000000935 antidepressant agent Substances 0.000 claims 1
• 229940005513 antidepressants Drugs 0.000 claims 1
• 239000004599 antimicrobial Substances 0.000 claims 1
• 239000000164 antipsychotic agent Substances 0.000 claims 1
• 229940005529 antipsychotics Drugs 0.000 claims 1
• 239000003435 antirheumatic agent Substances 0.000 claims 1
• 229940127225 asthma medication Drugs 0.000 claims 1
• 229940125388 beta agonist Drugs 0.000 claims 1
• 229960001265 ciclosporin Drugs 0.000 claims 1
• 239000002872 contrast media Substances 0.000 claims 1
• 239000003246 corticosteroid Substances 0.000 claims 1
• 230000000139 costimulatory effect Effects 0.000 claims 1
• 229930182912 cyclosporin Natural products 0.000 claims 1
• 239000002254 cytotoxic agent Substances 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 231100000599 cytotoxic agent Toxicity 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229960005139 epinephrine Drugs 0.000 claims 1
• 229940105423 erythropoietin Drugs 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• 239000000122 growth hormone Substances 0.000 claims 1
• 239000005556 hormone Substances 0.000 claims 1
• 229940088597 hormone Drugs 0.000 claims 1
• 230000003053 immunization Effects 0.000 claims 1
• 238000002649 immunization Methods 0.000 claims 1
• 102000018358 immunoglobulin Human genes 0.000 claims 1
• 229960003444 immunosuppressant agent Drugs 0.000 claims 1
• 230000001861 immunosuppressant effect Effects 0.000 claims 1
• 239000003018 immunosuppressive agent Substances 0.000 claims 1
• 229940043355 kinase inhibitor Drugs 0.000 claims 1
• 238000002690 local anesthesia Methods 0.000 claims 1
• 229960000485 methotrexate Drugs 0.000 claims 1
• 239000003158 myorelaxant agent Substances 0.000 claims 1
• 239000000842 neuromuscular blocking agent Substances 0.000 claims 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
• 239000000932 sedative agent Substances 0.000 claims 1
• 230000001624 sedative effect Effects 0.000 claims 1
• 229960002930 sirolimus Drugs 0.000 claims 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 230000003442 weekly effect Effects 0.000 claims 1